When a laboratory protocol is being tightened for a methods-writing week, the certificate of analysis can easily shrink into a single number. That number matters, but it is not the whole analytical story. For UK researchers and materials managers working with research-use-only peptides and laboratory tools, the more useful question is not only “what purity is printed on the front page?” but “which contaminant tests were requested, which sample they describe, and how the batch-specific documentation supports an in-vitro workflow?” These materials are not for human or veterinary use.
Why a Purity Headline Is Not a Screening Programme
A purity value, often expressed by HPLC, gives the reader a headline about the proportion of the principal peak in a particular analysis. Research Sciences’ current published wording includes a “≥99% Verified Purity” claim on the homepage and an FAQ statement that peptides are typically supplied at ≥99% purity by HPLC, with exact purity stated on the CoA. That is useful context, but it should be reconfirmed on the live site and, more importantly, on the CoA that accompanies the specific batch. A methods document needs to explain whether the value is batch-linked, which analytical method produced it, and whether identity and contaminant screening are reported alongside it. Without those details, a purity headline is a marketing summary, not a screening programme.
Contaminant screening is the part of the analytical conversation that tells a researcher what else may be present or what has been evaluated. The shop describes full-spectrum testing as purity, identity, heavy metals and endotoxin evaluation of submitted samples, and its blog guidance discusses heavy-metal testing in the context of ICP-MS and endotoxin testing as educational topics. Those are the kinds of categories to look for in the batch CoA. Researchers should not invent their own pass/fail limits from a headline; they should ask what the supplier actually tested, on which sample, and whether the report is batch-specific. The point is not to demand a single grand certificate, but to make the analytical scope visible in the protocol notes.
During methods-writing week, ask for the tests in writing. A supplier may publish a category page, a product page and a CoA; these serve different purposes. A product page describes the catalogue item, while the CoA should be opened for the batch. If a restock carries the same Internal Test Reference as earlier stock, remember the FAQ position: an ITR links to associated sample testing reports, but it does not confirm that separate deliveries came from the same production lot or that each delivery had separate independent testing. That distinction belongs in the methods appendix. For a current view of the UK catalogue, researchers can Buy peptides and then move to the individual product page and its batch CoA; the category page is a route to documentation, not a substitute for it.
Reading the CoA as a Methods Document, Not a Badge
A CoA is most useful when it is treated as a methods document. The shop states that it provides a CoA for every product, with HPLC for purity and identity, and describes independent testing and final UK verification before release. Where the homepage lists “CoAs Janoshik Analytical Reports”, the practical step is still to open and check the CoA that accompanies the specific batch; the listing alone is not the evidence. Researchers should record the product name, SKU or label reference, the CoA identifier and the analytical methods named in the report. If the CoA does not show the contaminant tests a project requires, the methods week is the moment to ask rather than assume.
Label discipline is part of the same chain. Vial labels use a reference format that combines the SKU code and expiry date, such as BPC10-03/27, and that reference links to the corresponding CoA. Quote it when contacting the shop about documentation. Do not use vial cap colour as an indicator of identity, analytical quality or manufacturing origin; packaging may vary, and cap colour is not an analytical result. For materials managers, the label reference and CoA should sit together in the batch file, alongside the storage and handling notes that apply to an in-vitro laboratory workflow.
Read beyond the pass column. A CoA may show a purity result and an identity result, but the contaminant section tells you whether heavy metals and endotoxin were evaluated for the submitted sample. The FAQ also notes that peptides contain trace amounts of mannitol as an excipient, used for stability during lyophilisation, solubility and protection in storage. Mannitol is not a contaminant, but it is part of the matrix, and it should be recognised in assay design and documentation. The methods narrative should distinguish between the principal material, excipients, and the contaminant tests requested. That separation keeps the write-up accurate and prevents a headline purity figure from doing work it cannot do. All materials remain research-use-only and are not for human or veterinary use.
Building Contaminant Screening into the Methods Week Workflow
A practical workflow starts with a documentation checklist for each catalogue item. First, confirm the product page and its research-use-only status. Second, open the batch CoA and note which tests are reported: purity, identity, heavy metals and endotoxin, where applicable. Third, match the vial label reference to the CoA and record it in the batch file. Fourth, note the storage instructions: lyophilised peptides should be stored at –20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided. Allow vials to reach room temperature before opening, work in a clean environment, and remove only the amount required for the experiment. If an in-vitro assay requires reconstitution, record the diluent volume and concentration in the laboratory protocol, not as a clinical or dosing instruction; the shop’s calculator and materials are for laboratory research use only.
Ask supplier questions that produce documentary answers. Which tests are batch-level? Which are sample-level? What does the ITR cover? Is the CoA supplied with the specific vial reference? Does the documentation identify heavy-metal and endotoxin evaluation, or only HPLC purity and identity? These questions are especially relevant in a methods-writing week because the answers shape the limitations section. If a published figure such as “≥99% Verified Purity” is quoted in an internal note, attribute it to the shop’s current published wording and reconfirm it against the batch CoA. Do not convert a marketing line into a laboratory specification without that check.
For materials managers, the final control is traceability. Keep the catalogue item, label reference, CoA, storage conditions and handling notes together, and make sure the methods text says which document was reviewed. Research Sciences operates as a UK supplier of research-use-only materials, with a catalogue that includes peptides and laboratory accessories; those items are not medicines, supplements or veterinary products. The laboratory’s responsibility includes lawful use, safe handling, storage and disposal, and compliance with relevant UK requirements such as COSHH. In a methods-writing week, that traceable chain—not the headline number alone—is what allows a contaminant-screening statement to stand up to review. The materials are not for human or veterinary use.